Serum Zinc & Acid Phosphatase Levels & Its Correlation in Patients of Benign & Malignant Prostatic Disease

Abstract

To determine the serum Zinc level in patients with benign prostatic hyperplasia (BPI-1) and prostatic carcinoma and its correlation with serum acid phosphatase. Methods: This was a case control study conducted in the Urology and General Surgery departments Isra University Hyderabad, during April 2016 to Nov: 2016.Total 100 male were studied. 25 patients with diagnosis of BPH and 25 diagnosed cases of prostatic carcinoma. while 50 normal cases were selected as a control. Blood samples were taken from all the patients and analyzed in the diagnostic and research laboratories of Isra University and LUMHS Hyderabad for serum zinc and serum acid phosphatase levels. Al I the clinical and demographic data was recorded on a proforma and statistically analyzed. Results: Mean serum acid phosphate levels were significantly raised in patients presented with BPH and prostate carcinoma as compare to normal study population p-value 0.0001. Though mean of serum acid phosphate level in patients with BP14 was 16.03±5.89 UIL and 46.43 6.22 U/L in patients presented with prostate carcinoma while 2.28± 0.99 UIL was in normal cases. Serum zinc was significantly decreased in patients having BPH and prostate cancer P-value 0.001. Week correlation was found between Prostate acid phosphate level and serum zinc level in normal cases r-value = 0.001. Negative correlation was found between Prostate acid phosphate level and serum zinc level in patients presented with BP1-1 and prostate carcinoma r-value — 0.071. Conclusion: It is concluded that prostatic acid phosphatase was significantly raised and serum Zinc levels significantly decreased in patients with BPH and carcinoma of prostate gland as compare to normal cases. Prostate acid phosphatase level and serum zinc level were negatively correlated between them.